Global Peptide API CDMO Services Supply, Demand and Key Producers, 2026-2032
The global Peptide API CDMO Services market size is expected to reach $ 13920 million by 2032, rising at a market growth of 18.7% CAGR during the forecast period (2026-2032).
Peptide API CDMO Services refer to outsourced development and manufacturing services for therapeutic peptide active pharmaceutical ingredients, typically covering discovery-scale synthesis, process development, analytical development and validation, quality studies, regulatory support, GMP scale-up, and commercial supply, with peptide drug substance rather than finished dosage forms as the primary deliverable. The upstream supply base mainly includes protected and specialty amino acids, solid-phase synthesis resins, coupling reagents, cleavage and deprotection reagents, organic solvents such as acetonitrile, purification media, analytical consumables, and GMP packaging materials, while the main downstream customers are innovative pharmaceutical companies, biotech firms, peptide generic and specialty drug developers, and manufacturers that formulate the API into injectable or other finished products. The 2025 gross margin of this segment showed wide dispersion because profitability depends heavily on development-stage mix, capacity utilization, commercial-scale execution, and process complexity; a realistic industry range is about 20%-55%, with development-heavy and high-value projects generally delivering higher margins, while platforms in large-scale ramp-up or major capacity expansion phases tend to report lower margins.
The peptide API CDMO services market is shifting from an outsourcing model centered mainly on early-stage development programs to a more integrated model covering process development, regulatory support, clinical supply, and commercial manufacturing. As peptide therapeutics continue to attract strong industry attention in metabolic disease, cardiovascular disease, oncology, and other chronic indications, customer requirements are becoming much more demanding. Buyers are no longer focused only on basic synthesis capability, but are placing greater emphasis on scale-up execution, impurity control, quality system maturity, and reliable long-term supply. For service providers, the ability to support a smooth transition from development to commercialization has become a critical part of market competitiveness.
On the supply side, the industry is moving toward greater scale, stronger platform integration, and more refined manufacturing capabilities. Peptide API production requires high standards in route design, purification efficiency, yield control, solvent management, and batch consistency, which is why leading companies continue to invest in production facilities, analytical capabilities, green process technologies, and quality management systems. At the same time, customers are paying closer attention to multi-region supply assurance and efficient technology transfer, making service providers with multi-site operations, solid validation experience, and strong engineering capability better positioned to win late-stage programs and long-term partnerships.
On the demand side, the market is being driven primarily by the continued expansion of peptide drug pipelines, the ramp-up of marketed products, and the increasing willingness of pharmaceutical and biotech companies to outsource complex molecule development and manufacturing. More innovators are relying on specialized CDMO platforms to reduce capital intensity, shorten development timelines, and lower execution risk during scale-up. In parallel, the growing use of long-acting designs, molecular modifications, and higher-complexity peptide structures is raising customer expectations for process expertise, regulatory support, and commercial manufacturing experience, creating broader opportunities for providers with strong end-to-end capabilities.
At the same time, the market still faces meaningful constraints and operational challenges. Peptide API manufacturing depends heavily on key raw materials, resins, coupling systems, purification media, and highly disciplined quality infrastructure, so supply chain volatility and cost pressure can easily affect manufacturing performance. In addition, although capacity expansion remains active across the industry, new facilities must still go through validation, ramp-up, customer qualification, and commercial transition before their value can be fully realized. Companies that fall short in process robustness, environmental and safety compliance, global regulatory readiness, or operational efficiency may struggle to convert new capacity into sustainable growth. In the future, competition will be determined not simply by scale, but by how well companies balance technical depth, project execution, quality assurance, delivery resilience, and cost control.
This report studies the global Peptide API CDMO Services demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Peptide API CDMO Services, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Peptide API CDMO Services that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Peptide API CDMO Services total market, 2021-2032, (USD Million)
Global Peptide API CDMO Services total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Peptide API CDMO Services total market, key domestic companies, and share, (USD Million)
Global Peptide API CDMO Services revenue by player, revenue and market share 2021-2026, (USD Million)
Global Peptide API CDMO Services total market by Type, CAGR, 2021-2032, (USD Million)
Global Peptide API CDMO Services total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Peptide API CDMO Services market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include PolyPeptide (CH), Bachem (CH), AmbioPharm (US), CordenPharma (CH), CPC Scientific (US), Piramal Pharma Solutions (IN), Almac Group (UK), Aspen API (ZA), Neuland Laboratories (IN), USV (IN), etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Peptide API CDMO Services market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Peptide API CDMO Services Market, By Region:
1. How big is the global Peptide API CDMO Services market?
2. What is the demand of the global Peptide API CDMO Services market?
3. What is the year over year growth of the global Peptide API CDMO Services market?
4. What is the total value of the global Peptide API CDMO Services market?
5. Who are the Major Players in the global Peptide API CDMO Services market?
6. What are the growth factors driving the market demand?
Peptide API CDMO Services refer to outsourced development and manufacturing services for therapeutic peptide active pharmaceutical ingredients, typically covering discovery-scale synthesis, process development, analytical development and validation, quality studies, regulatory support, GMP scale-up, and commercial supply, with peptide drug substance rather than finished dosage forms as the primary deliverable. The upstream supply base mainly includes protected and specialty amino acids, solid-phase synthesis resins, coupling reagents, cleavage and deprotection reagents, organic solvents such as acetonitrile, purification media, analytical consumables, and GMP packaging materials, while the main downstream customers are innovative pharmaceutical companies, biotech firms, peptide generic and specialty drug developers, and manufacturers that formulate the API into injectable or other finished products. The 2025 gross margin of this segment showed wide dispersion because profitability depends heavily on development-stage mix, capacity utilization, commercial-scale execution, and process complexity; a realistic industry range is about 20%-55%, with development-heavy and high-value projects generally delivering higher margins, while platforms in large-scale ramp-up or major capacity expansion phases tend to report lower margins.
The peptide API CDMO services market is shifting from an outsourcing model centered mainly on early-stage development programs to a more integrated model covering process development, regulatory support, clinical supply, and commercial manufacturing. As peptide therapeutics continue to attract strong industry attention in metabolic disease, cardiovascular disease, oncology, and other chronic indications, customer requirements are becoming much more demanding. Buyers are no longer focused only on basic synthesis capability, but are placing greater emphasis on scale-up execution, impurity control, quality system maturity, and reliable long-term supply. For service providers, the ability to support a smooth transition from development to commercialization has become a critical part of market competitiveness.
On the supply side, the industry is moving toward greater scale, stronger platform integration, and more refined manufacturing capabilities. Peptide API production requires high standards in route design, purification efficiency, yield control, solvent management, and batch consistency, which is why leading companies continue to invest in production facilities, analytical capabilities, green process technologies, and quality management systems. At the same time, customers are paying closer attention to multi-region supply assurance and efficient technology transfer, making service providers with multi-site operations, solid validation experience, and strong engineering capability better positioned to win late-stage programs and long-term partnerships.
On the demand side, the market is being driven primarily by the continued expansion of peptide drug pipelines, the ramp-up of marketed products, and the increasing willingness of pharmaceutical and biotech companies to outsource complex molecule development and manufacturing. More innovators are relying on specialized CDMO platforms to reduce capital intensity, shorten development timelines, and lower execution risk during scale-up. In parallel, the growing use of long-acting designs, molecular modifications, and higher-complexity peptide structures is raising customer expectations for process expertise, regulatory support, and commercial manufacturing experience, creating broader opportunities for providers with strong end-to-end capabilities.
At the same time, the market still faces meaningful constraints and operational challenges. Peptide API manufacturing depends heavily on key raw materials, resins, coupling systems, purification media, and highly disciplined quality infrastructure, so supply chain volatility and cost pressure can easily affect manufacturing performance. In addition, although capacity expansion remains active across the industry, new facilities must still go through validation, ramp-up, customer qualification, and commercial transition before their value can be fully realized. Companies that fall short in process robustness, environmental and safety compliance, global regulatory readiness, or operational efficiency may struggle to convert new capacity into sustainable growth. In the future, competition will be determined not simply by scale, but by how well companies balance technical depth, project execution, quality assurance, delivery resilience, and cost control.
This report studies the global Peptide API CDMO Services demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Peptide API CDMO Services, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Peptide API CDMO Services that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Peptide API CDMO Services total market, 2021-2032, (USD Million)
Global Peptide API CDMO Services total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Peptide API CDMO Services total market, key domestic companies, and share, (USD Million)
Global Peptide API CDMO Services revenue by player, revenue and market share 2021-2026, (USD Million)
Global Peptide API CDMO Services total market by Type, CAGR, 2021-2032, (USD Million)
Global Peptide API CDMO Services total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Peptide API CDMO Services market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include PolyPeptide (CH), Bachem (CH), AmbioPharm (US), CordenPharma (CH), CPC Scientific (US), Piramal Pharma Solutions (IN), Almac Group (UK), Aspen API (ZA), Neuland Laboratories (IN), USV (IN), etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Peptide API CDMO Services market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Peptide API CDMO Services Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- GMP Services
- Non-GMP Services
- SPPS
- LPPS
- Hybrid Technology
- Small-Scale (mg?g)
- Medium-Scale (g?kg)
- Large-Scale (kg?t)
- Commercial
- Scientific Research
- Other
- PolyPeptide (CH)
- Bachem (CH)
- AmbioPharm (US)
- CordenPharma (CH)
- CPC Scientific (US)
- Piramal Pharma Solutions (IN)
- Almac Group (UK)
- Aspen API (ZA)
- Neuland Laboratories (IN)
- USV (IN)
- Aurigene Pharmaceutical Services (IN)
- PeptiStar (JP)
- BCN Peptides (ES)
- Creative Peptides (US)
- Space Peptides (CH)
- Cambrex (US)
- Nippon Shokubai (JP)
- ScinoPharm (TW)
- ChengDu ShengNuo Biotec (CN)
- WuXi TIDES (CN)
- Asymchem (CN)
- Medtide (CN)
- Jiuzhou Pharma (CN)
- Hybio Pharmaceutical (CN)
- JYMed Peptide (CN)
1. How big is the global Peptide API CDMO Services market?
2. What is the demand of the global Peptide API CDMO Services market?
3. What is the year over year growth of the global Peptide API CDMO Services market?
4. What is the total value of the global Peptide API CDMO Services market?
5. Who are the Major Players in the global Peptide API CDMO Services market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Peptide API CDMO Services Introduction
1.2 World Peptide API CDMO Services Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Peptide API CDMO Services Total Market by Region (by Headquarter Location)
1.3.1 World Peptide API CDMO Services Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Peptide API CDMO Services Revenue (2021-2032)
1.3.3 China Based Company Peptide API CDMO Services Revenue (2021-2032)
1.3.4 Europe Based Company Peptide API CDMO Services Revenue (2021-2032)
1.3.5 Japan Based Company Peptide API CDMO Services Revenue (2021-2032)
1.3.6 South Korea Based Company Peptide API CDMO Services Revenue (2021-2032)
1.3.7 ASEAN Based Company Peptide API CDMO Services Revenue (2021-2032)
1.3.8 India Based Company Peptide API CDMO Services Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Peptide API CDMO Services Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Peptide API CDMO Services Consumption Value (2021-2032)
2.2 World Peptide API CDMO Services Consumption Value by Region
2.2.1 World Peptide API CDMO Services Consumption Value by Region (2021-2026)
2.2.2 World Peptide API CDMO Services Consumption Value Forecast by Region (2027-2032)
2.3 United States Peptide API CDMO Services Consumption Value (2021-2032)
2.4 China Peptide API CDMO Services Consumption Value (2021-2032)
2.5 Europe Peptide API CDMO Services Consumption Value (2021-2032)
2.6 Japan Peptide API CDMO Services Consumption Value (2021-2032)
2.7 South Korea Peptide API CDMO Services Consumption Value (2021-2032)
2.8 ASEAN Peptide API CDMO Services Consumption Value (2021-2032)
2.9 India Peptide API CDMO Services Consumption Value (2021-2032)
3 WORLD PEPTIDE API CDMO SERVICES COMPANIES COMPETITIVE ANALYSIS
3.1 World Peptide API CDMO Services Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Peptide API CDMO Services Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Peptide API CDMO Services in 2025
3.2.3 Global Concentration Ratios (CR8) for Peptide API CDMO Services in 2025
3.3 Peptide API CDMO Services Company Evaluation Quadrant
3.4 Peptide API CDMO Services Market: Overall Company Footprint Analysis
3.4.1 Peptide API CDMO Services Market: Region Footprint
3.4.2 Peptide API CDMO Services Market: Company Product Type Footprint
3.4.3 Peptide API CDMO Services Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Peptide API CDMO Services Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Peptide API CDMO Services Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Peptide API CDMO Services Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Peptide API CDMO Services Consumption Value Comparison
4.2.1 United States VS China: Peptide API CDMO Services Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Peptide API CDMO Services Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Peptide API CDMO Services Companies and Market Share, 2021-2026
4.3.1 United States Based Peptide API CDMO Services Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Peptide API CDMO Services Revenue, (2021-2026)
4.4 China Based Companies Peptide API CDMO Services Revenue and Market Share, 2021-2026
4.4.1 China Based Peptide API CDMO Services Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Peptide API CDMO Services Revenue, (2021-2026)
4.5 Rest of World Based Peptide API CDMO Services Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Peptide API CDMO Services Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Peptide API CDMO Services Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Peptide API CDMO Services Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 GMP Services
5.2.2 Non-GMP Services
5.3 Market Segment by Type
5.3.1 World Peptide API CDMO Services Market Size by Type (2021-2026)
5.3.2 World Peptide API CDMO Services Market Size by Type (2027-2032)
5.3.3 World Peptide API CDMO Services Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY SYNTHESIS TECHNOLOGY
6.1 World Peptide API CDMO Services Market Size Overview by Synthesis Technology: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Synthesis Technology
6.2.1 SPPS
6.2.2 LPPS
6.2.3 Hybrid Technology
6.3 Market Segment by Synthesis Technology
6.3.1 World Peptide API CDMO Services Market Size by Synthesis Technology (2021-2026)
6.3.2 World Peptide API CDMO Services Market Size by Synthesis Technology (2027-2032)
6.3.3 World Peptide API CDMO Services Market Size Market Share by Synthesis Technology (2027-2032)
7 MARKET ANALYSIS BY CAPACITY TIER
7.1 World Peptide API CDMO Services Market Size Overview by Capacity Tier: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Capacity Tier
7.2.1 Small-Scale (mg?g)
7.2.2 Medium-Scale (g?kg)
7.2.3 Large-Scale (kg?t)
7.3 Market Segment by Capacity Tier
7.3.1 World Peptide API CDMO Services Market Size by Capacity Tier (2021-2026)
7.3.2 World Peptide API CDMO Services Market Size by Capacity Tier (2027-2032)
7.3.3 World Peptide API CDMO Services Market Size Market Share by Capacity Tier (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Peptide API CDMO Services Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Commercial
8.2.2 Scientific Research
8.2.3 Other
8.3 Market Segment by Application
8.3.1 World Peptide API CDMO Services Market Size by Application (2021-2026)
8.3.2 World Peptide API CDMO Services Market Size by Application (2027-2032)
8.3.3 World Peptide API CDMO Services Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 PolyPeptide (CH)
9.1.1 PolyPeptide (CH) Details
9.1.2 PolyPeptide (CH) Major Business
9.1.3 PolyPeptide (CH) Peptide API CDMO Services Product and Services
9.1.4 PolyPeptide (CH) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 PolyPeptide (CH) Recent Developments/Updates
9.1.6 PolyPeptide (CH) Competitive Strengths & Weaknesses
9.2 Bachem (CH)
9.2.1 Bachem (CH) Details
9.2.2 Bachem (CH) Major Business
9.2.3 Bachem (CH) Peptide API CDMO Services Product and Services
9.2.4 Bachem (CH) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Bachem (CH) Recent Developments/Updates
9.2.6 Bachem (CH) Competitive Strengths & Weaknesses
9.3 AmbioPharm (US)
9.3.1 AmbioPharm (US) Details
9.3.2 AmbioPharm (US) Major Business
9.3.3 AmbioPharm (US) Peptide API CDMO Services Product and Services
9.3.4 AmbioPharm (US) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 AmbioPharm (US) Recent Developments/Updates
9.3.6 AmbioPharm (US) Competitive Strengths & Weaknesses
9.4 CordenPharma (CH)
9.4.1 CordenPharma (CH) Details
9.4.2 CordenPharma (CH) Major Business
9.4.3 CordenPharma (CH) Peptide API CDMO Services Product and Services
9.4.4 CordenPharma (CH) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 CordenPharma (CH) Recent Developments/Updates
9.4.6 CordenPharma (CH) Competitive Strengths & Weaknesses
9.5 CPC Scientific (US)
9.5.1 CPC Scientific (US) Details
9.5.2 CPC Scientific (US) Major Business
9.5.3 CPC Scientific (US) Peptide API CDMO Services Product and Services
9.5.4 CPC Scientific (US) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 CPC Scientific (US) Recent Developments/Updates
9.5.6 CPC Scientific (US) Competitive Strengths & Weaknesses
9.6 Piramal Pharma Solutions (IN)
9.6.1 Piramal Pharma Solutions (IN) Details
9.6.2 Piramal Pharma Solutions (IN) Major Business
9.6.3 Piramal Pharma Solutions (IN) Peptide API CDMO Services Product and Services
9.6.4 Piramal Pharma Solutions (IN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 Piramal Pharma Solutions (IN) Recent Developments/Updates
9.6.6 Piramal Pharma Solutions (IN) Competitive Strengths & Weaknesses
9.7 Almac Group (UK)
9.7.1 Almac Group (UK) Details
9.7.2 Almac Group (UK) Major Business
9.7.3 Almac Group (UK) Peptide API CDMO Services Product and Services
9.7.4 Almac Group (UK) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 Almac Group (UK) Recent Developments/Updates
9.7.6 Almac Group (UK) Competitive Strengths & Weaknesses
9.8 Aspen API (ZA)
9.8.1 Aspen API (ZA) Details
9.8.2 Aspen API (ZA) Major Business
9.8.3 Aspen API (ZA) Peptide API CDMO Services Product and Services
9.8.4 Aspen API (ZA) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Aspen API (ZA) Recent Developments/Updates
9.8.6 Aspen API (ZA) Competitive Strengths & Weaknesses
9.9 Neuland Laboratories (IN)
9.9.1 Neuland Laboratories (IN) Details
9.9.2 Neuland Laboratories (IN) Major Business
9.9.3 Neuland Laboratories (IN) Peptide API CDMO Services Product and Services
9.9.4 Neuland Laboratories (IN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 Neuland Laboratories (IN) Recent Developments/Updates
9.9.6 Neuland Laboratories (IN) Competitive Strengths & Weaknesses
9.10 USV (IN)
9.10.1 USV (IN) Details
9.10.2 USV (IN) Major Business
9.10.3 USV (IN) Peptide API CDMO Services Product and Services
9.10.4 USV (IN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 USV (IN) Recent Developments/Updates
9.10.6 USV (IN) Competitive Strengths & Weaknesses
9.11 Aurigene Pharmaceutical Services (IN)
9.11.1 Aurigene Pharmaceutical Services (IN) Details
9.11.2 Aurigene Pharmaceutical Services (IN) Major Business
9.11.3 Aurigene Pharmaceutical Services (IN) Peptide API CDMO Services Product and Services
9.11.4 Aurigene Pharmaceutical Services (IN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.11.5 Aurigene Pharmaceutical Services (IN) Recent Developments/Updates
9.11.6 Aurigene Pharmaceutical Services (IN) Competitive Strengths & Weaknesses
9.12 PeptiStar (JP)
9.12.1 PeptiStar (JP) Details
9.12.2 PeptiStar (JP) Major Business
9.12.3 PeptiStar (JP) Peptide API CDMO Services Product and Services
9.12.4 PeptiStar (JP) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.12.5 PeptiStar (JP) Recent Developments/Updates
9.12.6 PeptiStar (JP) Competitive Strengths & Weaknesses
9.13 BCN Peptides (ES)
9.13.1 BCN Peptides (ES) Details
9.13.2 BCN Peptides (ES) Major Business
9.13.3 BCN Peptides (ES) Peptide API CDMO Services Product and Services
9.13.4 BCN Peptides (ES) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.13.5 BCN Peptides (ES) Recent Developments/Updates
9.13.6 BCN Peptides (ES) Competitive Strengths & Weaknesses
9.14 Creative Peptides (US)
9.14.1 Creative Peptides (US) Details
9.14.2 Creative Peptides (US) Major Business
9.14.3 Creative Peptides (US) Peptide API CDMO Services Product and Services
9.14.4 Creative Peptides (US) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.14.5 Creative Peptides (US) Recent Developments/Updates
9.14.6 Creative Peptides (US) Competitive Strengths & Weaknesses
9.15 Space Peptides (CH)
9.15.1 Space Peptides (CH) Details
9.15.2 Space Peptides (CH) Major Business
9.15.3 Space Peptides (CH) Peptide API CDMO Services Product and Services
9.15.4 Space Peptides (CH) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.15.5 Space Peptides (CH) Recent Developments/Updates
9.15.6 Space Peptides (CH) Competitive Strengths & Weaknesses
9.16 Cambrex (US)
9.16.1 Cambrex (US) Details
9.16.2 Cambrex (US) Major Business
9.16.3 Cambrex (US) Peptide API CDMO Services Product and Services
9.16.4 Cambrex (US) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.16.5 Cambrex (US) Recent Developments/Updates
9.16.6 Cambrex (US) Competitive Strengths & Weaknesses
9.17 Nippon Shokubai (JP)
9.17.1 Nippon Shokubai (JP) Details
9.17.2 Nippon Shokubai (JP) Major Business
9.17.3 Nippon Shokubai (JP) Peptide API CDMO Services Product and Services
9.17.4 Nippon Shokubai (JP) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.17.5 Nippon Shokubai (JP) Recent Developments/Updates
9.17.6 Nippon Shokubai (JP) Competitive Strengths & Weaknesses
9.18 ScinoPharm (TW)
9.18.1 ScinoPharm (TW) Details
9.18.2 ScinoPharm (TW) Major Business
9.18.3 ScinoPharm (TW) Peptide API CDMO Services Product and Services
9.18.4 ScinoPharm (TW) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.18.5 ScinoPharm (TW) Recent Developments/Updates
9.18.6 ScinoPharm (TW) Competitive Strengths & Weaknesses
9.19 ChengDu ShengNuo Biotec (CN)
9.19.1 ChengDu ShengNuo Biotec (CN) Details
9.19.2 ChengDu ShengNuo Biotec (CN) Major Business
9.19.3 ChengDu ShengNuo Biotec (CN) Peptide API CDMO Services Product and Services
9.19.4 ChengDu ShengNuo Biotec (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.19.5 ChengDu ShengNuo Biotec (CN) Recent Developments/Updates
9.19.6 ChengDu ShengNuo Biotec (CN) Competitive Strengths & Weaknesses
9.20 WuXi TIDES (CN)
9.20.1 WuXi TIDES (CN) Details
9.20.2 WuXi TIDES (CN) Major Business
9.20.3 WuXi TIDES (CN) Peptide API CDMO Services Product and Services
9.20.4 WuXi TIDES (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.20.5 WuXi TIDES (CN) Recent Developments/Updates
9.20.6 WuXi TIDES (CN) Competitive Strengths & Weaknesses
9.21 Asymchem (CN)
9.21.1 Asymchem (CN) Details
9.21.2 Asymchem (CN) Major Business
9.21.3 Asymchem (CN) Peptide API CDMO Services Product and Services
9.21.4 Asymchem (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.21.5 Asymchem (CN) Recent Developments/Updates
9.21.6 Asymchem (CN) Competitive Strengths & Weaknesses
9.22 Medtide (CN)
9.22.1 Medtide (CN) Details
9.22.2 Medtide (CN) Major Business
9.22.3 Medtide (CN) Peptide API CDMO Services Product and Services
9.22.4 Medtide (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.22.5 Medtide (CN) Recent Developments/Updates
9.22.6 Medtide (CN) Competitive Strengths & Weaknesses
9.23 Jiuzhou Pharma (CN)
9.23.1 Jiuzhou Pharma (CN) Details
9.23.2 Jiuzhou Pharma (CN) Major Business
9.23.3 Jiuzhou Pharma (CN) Peptide API CDMO Services Product and Services
9.23.4 Jiuzhou Pharma (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.23.5 Jiuzhou Pharma (CN) Recent Developments/Updates
9.23.6 Jiuzhou Pharma (CN) Competitive Strengths & Weaknesses
9.24 Hybio Pharmaceutical (CN)
9.24.1 Hybio Pharmaceutical (CN) Details
9.24.2 Hybio Pharmaceutical (CN) Major Business
9.24.3 Hybio Pharmaceutical (CN) Peptide API CDMO Services Product and Services
9.24.4 Hybio Pharmaceutical (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.24.5 Hybio Pharmaceutical (CN) Recent Developments/Updates
9.24.6 Hybio Pharmaceutical (CN) Competitive Strengths & Weaknesses
9.25 JYMed Peptide (CN)
9.25.1 JYMed Peptide (CN) Details
9.25.2 JYMed Peptide (CN) Major Business
9.25.3 JYMed Peptide (CN) Peptide API CDMO Services Product and Services
9.25.4 JYMed Peptide (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.25.5 JYMed Peptide (CN) Recent Developments/Updates
9.25.6 JYMed Peptide (CN) Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Peptide API CDMO Services Industry Chain
10.2 Peptide API CDMO Services Upstream Analysis
10.3 Peptide API CDMO Services Midstream Analysis
10.4 Peptide API CDMO Services Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Peptide API CDMO Services Introduction
1.2 World Peptide API CDMO Services Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Peptide API CDMO Services Total Market by Region (by Headquarter Location)
1.3.1 World Peptide API CDMO Services Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Peptide API CDMO Services Revenue (2021-2032)
1.3.3 China Based Company Peptide API CDMO Services Revenue (2021-2032)
1.3.4 Europe Based Company Peptide API CDMO Services Revenue (2021-2032)
1.3.5 Japan Based Company Peptide API CDMO Services Revenue (2021-2032)
1.3.6 South Korea Based Company Peptide API CDMO Services Revenue (2021-2032)
1.3.7 ASEAN Based Company Peptide API CDMO Services Revenue (2021-2032)
1.3.8 India Based Company Peptide API CDMO Services Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Peptide API CDMO Services Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Peptide API CDMO Services Consumption Value (2021-2032)
2.2 World Peptide API CDMO Services Consumption Value by Region
2.2.1 World Peptide API CDMO Services Consumption Value by Region (2021-2026)
2.2.2 World Peptide API CDMO Services Consumption Value Forecast by Region (2027-2032)
2.3 United States Peptide API CDMO Services Consumption Value (2021-2032)
2.4 China Peptide API CDMO Services Consumption Value (2021-2032)
2.5 Europe Peptide API CDMO Services Consumption Value (2021-2032)
2.6 Japan Peptide API CDMO Services Consumption Value (2021-2032)
2.7 South Korea Peptide API CDMO Services Consumption Value (2021-2032)
2.8 ASEAN Peptide API CDMO Services Consumption Value (2021-2032)
2.9 India Peptide API CDMO Services Consumption Value (2021-2032)
3 WORLD PEPTIDE API CDMO SERVICES COMPANIES COMPETITIVE ANALYSIS
3.1 World Peptide API CDMO Services Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Peptide API CDMO Services Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Peptide API CDMO Services in 2025
3.2.3 Global Concentration Ratios (CR8) for Peptide API CDMO Services in 2025
3.3 Peptide API CDMO Services Company Evaluation Quadrant
3.4 Peptide API CDMO Services Market: Overall Company Footprint Analysis
3.4.1 Peptide API CDMO Services Market: Region Footprint
3.4.2 Peptide API CDMO Services Market: Company Product Type Footprint
3.4.3 Peptide API CDMO Services Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Peptide API CDMO Services Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Peptide API CDMO Services Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Peptide API CDMO Services Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Peptide API CDMO Services Consumption Value Comparison
4.2.1 United States VS China: Peptide API CDMO Services Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Peptide API CDMO Services Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Peptide API CDMO Services Companies and Market Share, 2021-2026
4.3.1 United States Based Peptide API CDMO Services Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Peptide API CDMO Services Revenue, (2021-2026)
4.4 China Based Companies Peptide API CDMO Services Revenue and Market Share, 2021-2026
4.4.1 China Based Peptide API CDMO Services Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Peptide API CDMO Services Revenue, (2021-2026)
4.5 Rest of World Based Peptide API CDMO Services Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Peptide API CDMO Services Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Peptide API CDMO Services Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Peptide API CDMO Services Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 GMP Services
5.2.2 Non-GMP Services
5.3 Market Segment by Type
5.3.1 World Peptide API CDMO Services Market Size by Type (2021-2026)
5.3.2 World Peptide API CDMO Services Market Size by Type (2027-2032)
5.3.3 World Peptide API CDMO Services Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY SYNTHESIS TECHNOLOGY
6.1 World Peptide API CDMO Services Market Size Overview by Synthesis Technology: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Synthesis Technology
6.2.1 SPPS
6.2.2 LPPS
6.2.3 Hybrid Technology
6.3 Market Segment by Synthesis Technology
6.3.1 World Peptide API CDMO Services Market Size by Synthesis Technology (2021-2026)
6.3.2 World Peptide API CDMO Services Market Size by Synthesis Technology (2027-2032)
6.3.3 World Peptide API CDMO Services Market Size Market Share by Synthesis Technology (2027-2032)
7 MARKET ANALYSIS BY CAPACITY TIER
7.1 World Peptide API CDMO Services Market Size Overview by Capacity Tier: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Capacity Tier
7.2.1 Small-Scale (mg?g)
7.2.2 Medium-Scale (g?kg)
7.2.3 Large-Scale (kg?t)
7.3 Market Segment by Capacity Tier
7.3.1 World Peptide API CDMO Services Market Size by Capacity Tier (2021-2026)
7.3.2 World Peptide API CDMO Services Market Size by Capacity Tier (2027-2032)
7.3.3 World Peptide API CDMO Services Market Size Market Share by Capacity Tier (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Peptide API CDMO Services Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Commercial
8.2.2 Scientific Research
8.2.3 Other
8.3 Market Segment by Application
8.3.1 World Peptide API CDMO Services Market Size by Application (2021-2026)
8.3.2 World Peptide API CDMO Services Market Size by Application (2027-2032)
8.3.3 World Peptide API CDMO Services Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 PolyPeptide (CH)
9.1.1 PolyPeptide (CH) Details
9.1.2 PolyPeptide (CH) Major Business
9.1.3 PolyPeptide (CH) Peptide API CDMO Services Product and Services
9.1.4 PolyPeptide (CH) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 PolyPeptide (CH) Recent Developments/Updates
9.1.6 PolyPeptide (CH) Competitive Strengths & Weaknesses
9.2 Bachem (CH)
9.2.1 Bachem (CH) Details
9.2.2 Bachem (CH) Major Business
9.2.3 Bachem (CH) Peptide API CDMO Services Product and Services
9.2.4 Bachem (CH) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Bachem (CH) Recent Developments/Updates
9.2.6 Bachem (CH) Competitive Strengths & Weaknesses
9.3 AmbioPharm (US)
9.3.1 AmbioPharm (US) Details
9.3.2 AmbioPharm (US) Major Business
9.3.3 AmbioPharm (US) Peptide API CDMO Services Product and Services
9.3.4 AmbioPharm (US) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 AmbioPharm (US) Recent Developments/Updates
9.3.6 AmbioPharm (US) Competitive Strengths & Weaknesses
9.4 CordenPharma (CH)
9.4.1 CordenPharma (CH) Details
9.4.2 CordenPharma (CH) Major Business
9.4.3 CordenPharma (CH) Peptide API CDMO Services Product and Services
9.4.4 CordenPharma (CH) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 CordenPharma (CH) Recent Developments/Updates
9.4.6 CordenPharma (CH) Competitive Strengths & Weaknesses
9.5 CPC Scientific (US)
9.5.1 CPC Scientific (US) Details
9.5.2 CPC Scientific (US) Major Business
9.5.3 CPC Scientific (US) Peptide API CDMO Services Product and Services
9.5.4 CPC Scientific (US) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 CPC Scientific (US) Recent Developments/Updates
9.5.6 CPC Scientific (US) Competitive Strengths & Weaknesses
9.6 Piramal Pharma Solutions (IN)
9.6.1 Piramal Pharma Solutions (IN) Details
9.6.2 Piramal Pharma Solutions (IN) Major Business
9.6.3 Piramal Pharma Solutions (IN) Peptide API CDMO Services Product and Services
9.6.4 Piramal Pharma Solutions (IN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 Piramal Pharma Solutions (IN) Recent Developments/Updates
9.6.6 Piramal Pharma Solutions (IN) Competitive Strengths & Weaknesses
9.7 Almac Group (UK)
9.7.1 Almac Group (UK) Details
9.7.2 Almac Group (UK) Major Business
9.7.3 Almac Group (UK) Peptide API CDMO Services Product and Services
9.7.4 Almac Group (UK) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 Almac Group (UK) Recent Developments/Updates
9.7.6 Almac Group (UK) Competitive Strengths & Weaknesses
9.8 Aspen API (ZA)
9.8.1 Aspen API (ZA) Details
9.8.2 Aspen API (ZA) Major Business
9.8.3 Aspen API (ZA) Peptide API CDMO Services Product and Services
9.8.4 Aspen API (ZA) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Aspen API (ZA) Recent Developments/Updates
9.8.6 Aspen API (ZA) Competitive Strengths & Weaknesses
9.9 Neuland Laboratories (IN)
9.9.1 Neuland Laboratories (IN) Details
9.9.2 Neuland Laboratories (IN) Major Business
9.9.3 Neuland Laboratories (IN) Peptide API CDMO Services Product and Services
9.9.4 Neuland Laboratories (IN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 Neuland Laboratories (IN) Recent Developments/Updates
9.9.6 Neuland Laboratories (IN) Competitive Strengths & Weaknesses
9.10 USV (IN)
9.10.1 USV (IN) Details
9.10.2 USV (IN) Major Business
9.10.3 USV (IN) Peptide API CDMO Services Product and Services
9.10.4 USV (IN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 USV (IN) Recent Developments/Updates
9.10.6 USV (IN) Competitive Strengths & Weaknesses
9.11 Aurigene Pharmaceutical Services (IN)
9.11.1 Aurigene Pharmaceutical Services (IN) Details
9.11.2 Aurigene Pharmaceutical Services (IN) Major Business
9.11.3 Aurigene Pharmaceutical Services (IN) Peptide API CDMO Services Product and Services
9.11.4 Aurigene Pharmaceutical Services (IN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.11.5 Aurigene Pharmaceutical Services (IN) Recent Developments/Updates
9.11.6 Aurigene Pharmaceutical Services (IN) Competitive Strengths & Weaknesses
9.12 PeptiStar (JP)
9.12.1 PeptiStar (JP) Details
9.12.2 PeptiStar (JP) Major Business
9.12.3 PeptiStar (JP) Peptide API CDMO Services Product and Services
9.12.4 PeptiStar (JP) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.12.5 PeptiStar (JP) Recent Developments/Updates
9.12.6 PeptiStar (JP) Competitive Strengths & Weaknesses
9.13 BCN Peptides (ES)
9.13.1 BCN Peptides (ES) Details
9.13.2 BCN Peptides (ES) Major Business
9.13.3 BCN Peptides (ES) Peptide API CDMO Services Product and Services
9.13.4 BCN Peptides (ES) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.13.5 BCN Peptides (ES) Recent Developments/Updates
9.13.6 BCN Peptides (ES) Competitive Strengths & Weaknesses
9.14 Creative Peptides (US)
9.14.1 Creative Peptides (US) Details
9.14.2 Creative Peptides (US) Major Business
9.14.3 Creative Peptides (US) Peptide API CDMO Services Product and Services
9.14.4 Creative Peptides (US) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.14.5 Creative Peptides (US) Recent Developments/Updates
9.14.6 Creative Peptides (US) Competitive Strengths & Weaknesses
9.15 Space Peptides (CH)
9.15.1 Space Peptides (CH) Details
9.15.2 Space Peptides (CH) Major Business
9.15.3 Space Peptides (CH) Peptide API CDMO Services Product and Services
9.15.4 Space Peptides (CH) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.15.5 Space Peptides (CH) Recent Developments/Updates
9.15.6 Space Peptides (CH) Competitive Strengths & Weaknesses
9.16 Cambrex (US)
9.16.1 Cambrex (US) Details
9.16.2 Cambrex (US) Major Business
9.16.3 Cambrex (US) Peptide API CDMO Services Product and Services
9.16.4 Cambrex (US) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.16.5 Cambrex (US) Recent Developments/Updates
9.16.6 Cambrex (US) Competitive Strengths & Weaknesses
9.17 Nippon Shokubai (JP)
9.17.1 Nippon Shokubai (JP) Details
9.17.2 Nippon Shokubai (JP) Major Business
9.17.3 Nippon Shokubai (JP) Peptide API CDMO Services Product and Services
9.17.4 Nippon Shokubai (JP) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.17.5 Nippon Shokubai (JP) Recent Developments/Updates
9.17.6 Nippon Shokubai (JP) Competitive Strengths & Weaknesses
9.18 ScinoPharm (TW)
9.18.1 ScinoPharm (TW) Details
9.18.2 ScinoPharm (TW) Major Business
9.18.3 ScinoPharm (TW) Peptide API CDMO Services Product and Services
9.18.4 ScinoPharm (TW) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.18.5 ScinoPharm (TW) Recent Developments/Updates
9.18.6 ScinoPharm (TW) Competitive Strengths & Weaknesses
9.19 ChengDu ShengNuo Biotec (CN)
9.19.1 ChengDu ShengNuo Biotec (CN) Details
9.19.2 ChengDu ShengNuo Biotec (CN) Major Business
9.19.3 ChengDu ShengNuo Biotec (CN) Peptide API CDMO Services Product and Services
9.19.4 ChengDu ShengNuo Biotec (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.19.5 ChengDu ShengNuo Biotec (CN) Recent Developments/Updates
9.19.6 ChengDu ShengNuo Biotec (CN) Competitive Strengths & Weaknesses
9.20 WuXi TIDES (CN)
9.20.1 WuXi TIDES (CN) Details
9.20.2 WuXi TIDES (CN) Major Business
9.20.3 WuXi TIDES (CN) Peptide API CDMO Services Product and Services
9.20.4 WuXi TIDES (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.20.5 WuXi TIDES (CN) Recent Developments/Updates
9.20.6 WuXi TIDES (CN) Competitive Strengths & Weaknesses
9.21 Asymchem (CN)
9.21.1 Asymchem (CN) Details
9.21.2 Asymchem (CN) Major Business
9.21.3 Asymchem (CN) Peptide API CDMO Services Product and Services
9.21.4 Asymchem (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.21.5 Asymchem (CN) Recent Developments/Updates
9.21.6 Asymchem (CN) Competitive Strengths & Weaknesses
9.22 Medtide (CN)
9.22.1 Medtide (CN) Details
9.22.2 Medtide (CN) Major Business
9.22.3 Medtide (CN) Peptide API CDMO Services Product and Services
9.22.4 Medtide (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.22.5 Medtide (CN) Recent Developments/Updates
9.22.6 Medtide (CN) Competitive Strengths & Weaknesses
9.23 Jiuzhou Pharma (CN)
9.23.1 Jiuzhou Pharma (CN) Details
9.23.2 Jiuzhou Pharma (CN) Major Business
9.23.3 Jiuzhou Pharma (CN) Peptide API CDMO Services Product and Services
9.23.4 Jiuzhou Pharma (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.23.5 Jiuzhou Pharma (CN) Recent Developments/Updates
9.23.6 Jiuzhou Pharma (CN) Competitive Strengths & Weaknesses
9.24 Hybio Pharmaceutical (CN)
9.24.1 Hybio Pharmaceutical (CN) Details
9.24.2 Hybio Pharmaceutical (CN) Major Business
9.24.3 Hybio Pharmaceutical (CN) Peptide API CDMO Services Product and Services
9.24.4 Hybio Pharmaceutical (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.24.5 Hybio Pharmaceutical (CN) Recent Developments/Updates
9.24.6 Hybio Pharmaceutical (CN) Competitive Strengths & Weaknesses
9.25 JYMed Peptide (CN)
9.25.1 JYMed Peptide (CN) Details
9.25.2 JYMed Peptide (CN) Major Business
9.25.3 JYMed Peptide (CN) Peptide API CDMO Services Product and Services
9.25.4 JYMed Peptide (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
9.25.5 JYMed Peptide (CN) Recent Developments/Updates
9.25.6 JYMed Peptide (CN) Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Peptide API CDMO Services Industry Chain
10.2 Peptide API CDMO Services Upstream Analysis
10.3 Peptide API CDMO Services Midstream Analysis
10.4 Peptide API CDMO Services Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World Peptide API CDMO Services Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Peptide API CDMO Services Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Peptide API CDMO Services Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Peptide API CDMO Services Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Peptide API CDMO Services Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Peptide API CDMO Services Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Peptide API CDMO Services Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Peptide API CDMO Services Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Peptide API CDMO Services Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Peptide API CDMO Services Players in 2025
Table 12. World Peptide API CDMO Services Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Peptide API CDMO Services Company Evaluation Quadrant
Table 14. Head Office of Key Peptide API CDMO Services Players
Table 15. Peptide API CDMO Services Market: Company Product Type Footprint
Table 16. Peptide API CDMO Services Market: Company Product Application Footprint
Table 17. Peptide API CDMO Services Mergers & Acquisitions Activity
Table 18. United States VS China Peptide API CDMO Services Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Peptide API CDMO Services Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Peptide API CDMO Services Companies, Headquarters (States, Country)
Table 21. United States Based Companies Peptide API CDMO Services Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Peptide API CDMO Services Revenue Market Share (2021-2026)
Table 23. China Based Peptide API CDMO Services Companies, Headquarters (Province, Country)
Table 24. China Based Companies Peptide API CDMO Services Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Peptide API CDMO Services Revenue Market Share (2021-2026)
Table 26. Rest of World Based Peptide API CDMO Services Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Peptide API CDMO Services Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Peptide API CDMO Services Revenue Market Share (2021-2026)
Table 29. World Peptide API CDMO Services Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Peptide API CDMO Services Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Peptide API CDMO Services Market Size by Type (2027-2032) & (USD Million)
Table 32. World Peptide API CDMO Services Market Size by Synthesis Technology, (USD Million), 2021 & 2025 & 2032
Table 33. World Peptide API CDMO Services Market Size Value by Synthesis Technology (2021-2026) & (USD Million)
Table 34. World Peptide API CDMO Services Market Size by Synthesis Technology (2027-2032) & (USD Million)
Table 35. World Peptide API CDMO Services Market Size by Capacity Tier, (USD Million), 2021 & 2025 & 2032
Table 36. World Peptide API CDMO Services Market Size Value by Capacity Tier (2021-2026) & (USD Million)
Table 37. World Peptide API CDMO Services Market Size by Capacity Tier (2027-2032) & (USD Million)
Table 38. World Peptide API CDMO Services Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Peptide API CDMO Services Market Size by Application (2021-2026) & (USD Million)
Table 40. World Peptide API CDMO Services Market Size by Application (2027-2032) & (USD Million)
Table 41. PolyPeptide (CH) Basic Information, Manufacturing Base and Competitors
Table 42. PolyPeptide (CH) Major Business
Table 43. PolyPeptide (CH) Peptide API CDMO Services Product and Services
Table 44. PolyPeptide (CH) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. PolyPeptide (CH) Recent Developments/Updates
Table 46. PolyPeptide (CH) Competitive Strengths & Weaknesses
Table 47. Bachem (CH) Basic Information, Manufacturing Base and Competitors
Table 48. Bachem (CH) Major Business
Table 49. Bachem (CH) Peptide API CDMO Services Product and Services
Table 50. Bachem (CH) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Bachem (CH) Recent Developments/Updates
Table 52. Bachem (CH) Competitive Strengths & Weaknesses
Table 53. AmbioPharm (US) Basic Information, Manufacturing Base and Competitors
Table 54. AmbioPharm (US) Major Business
Table 55. AmbioPharm (US) Peptide API CDMO Services Product and Services
Table 56. AmbioPharm (US) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. AmbioPharm (US) Recent Developments/Updates
Table 58. AmbioPharm (US) Competitive Strengths & Weaknesses
Table 59. CordenPharma (CH) Basic Information, Manufacturing Base and Competitors
Table 60. CordenPharma (CH) Major Business
Table 61. CordenPharma (CH) Peptide API CDMO Services Product and Services
Table 62. CordenPharma (CH) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. CordenPharma (CH) Recent Developments/Updates
Table 64. CordenPharma (CH) Competitive Strengths & Weaknesses
Table 65. CPC Scientific (US) Basic Information, Manufacturing Base and Competitors
Table 66. CPC Scientific (US) Major Business
Table 67. CPC Scientific (US) Peptide API CDMO Services Product and Services
Table 68. CPC Scientific (US) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. CPC Scientific (US) Recent Developments/Updates
Table 70. CPC Scientific (US) Competitive Strengths & Weaknesses
Table 71. Piramal Pharma Solutions (IN) Basic Information, Manufacturing Base and Competitors
Table 72. Piramal Pharma Solutions (IN) Major Business
Table 73. Piramal Pharma Solutions (IN) Peptide API CDMO Services Product and Services
Table 74. Piramal Pharma Solutions (IN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Piramal Pharma Solutions (IN) Recent Developments/Updates
Table 76. Piramal Pharma Solutions (IN) Competitive Strengths & Weaknesses
Table 77. Almac Group (UK) Basic Information, Manufacturing Base and Competitors
Table 78. Almac Group (UK) Major Business
Table 79. Almac Group (UK) Peptide API CDMO Services Product and Services
Table 80. Almac Group (UK) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Almac Group (UK) Recent Developments/Updates
Table 82. Almac Group (UK) Competitive Strengths & Weaknesses
Table 83. Aspen API (ZA) Basic Information, Manufacturing Base and Competitors
Table 84. Aspen API (ZA) Major Business
Table 85. Aspen API (ZA) Peptide API CDMO Services Product and Services
Table 86. Aspen API (ZA) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Aspen API (ZA) Recent Developments/Updates
Table 88. Aspen API (ZA) Competitive Strengths & Weaknesses
Table 89. Neuland Laboratories (IN) Basic Information, Manufacturing Base and Competitors
Table 90. Neuland Laboratories (IN) Major Business
Table 91. Neuland Laboratories (IN) Peptide API CDMO Services Product and Services
Table 92. Neuland Laboratories (IN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Neuland Laboratories (IN) Recent Developments/Updates
Table 94. Neuland Laboratories (IN) Competitive Strengths & Weaknesses
Table 95. USV (IN) Basic Information, Manufacturing Base and Competitors
Table 96. USV (IN) Major Business
Table 97. USV (IN) Peptide API CDMO Services Product and Services
Table 98. USV (IN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. USV (IN) Recent Developments/Updates
Table 100. USV (IN) Competitive Strengths & Weaknesses
Table 101. Aurigene Pharmaceutical Services (IN) Basic Information, Manufacturing Base and Competitors
Table 102. Aurigene Pharmaceutical Services (IN) Major Business
Table 103. Aurigene Pharmaceutical Services (IN) Peptide API CDMO Services Product and Services
Table 104. Aurigene Pharmaceutical Services (IN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. Aurigene Pharmaceutical Services (IN) Recent Developments/Updates
Table 106. Aurigene Pharmaceutical Services (IN) Competitive Strengths & Weaknesses
Table 107. PeptiStar (JP) Basic Information, Manufacturing Base and Competitors
Table 108. PeptiStar (JP) Major Business
Table 109. PeptiStar (JP) Peptide API CDMO Services Product and Services
Table 110. PeptiStar (JP) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. PeptiStar (JP) Recent Developments/Updates
Table 112. PeptiStar (JP) Competitive Strengths & Weaknesses
Table 113. BCN Peptides (ES) Basic Information, Manufacturing Base and Competitors
Table 114. BCN Peptides (ES) Major Business
Table 115. BCN Peptides (ES) Peptide API CDMO Services Product and Services
Table 116. BCN Peptides (ES) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 117. BCN Peptides (ES) Recent Developments/Updates
Table 118. BCN Peptides (ES) Competitive Strengths & Weaknesses
Table 119. Creative Peptides (US) Basic Information, Manufacturing Base and Competitors
Table 120. Creative Peptides (US) Major Business
Table 121. Creative Peptides (US) Peptide API CDMO Services Product and Services
Table 122. Creative Peptides (US) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 123. Creative Peptides (US) Recent Developments/Updates
Table 124. Creative Peptides (US) Competitive Strengths & Weaknesses
Table 125. Space Peptides (CH) Basic Information, Manufacturing Base and Competitors
Table 126. Space Peptides (CH) Major Business
Table 127. Space Peptides (CH) Peptide API CDMO Services Product and Services
Table 128. Space Peptides (CH) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 129. Space Peptides (CH) Recent Developments/Updates
Table 130. Space Peptides (CH) Competitive Strengths & Weaknesses
Table 131. Cambrex (US) Basic Information, Manufacturing Base and Competitors
Table 132. Cambrex (US) Major Business
Table 133. Cambrex (US) Peptide API CDMO Services Product and Services
Table 134. Cambrex (US) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 135. Cambrex (US) Recent Developments/Updates
Table 136. Cambrex (US) Competitive Strengths & Weaknesses
Table 137. Nippon Shokubai (JP) Basic Information, Manufacturing Base and Competitors
Table 138. Nippon Shokubai (JP) Major Business
Table 139. Nippon Shokubai (JP) Peptide API CDMO Services Product and Services
Table 140. Nippon Shokubai (JP) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 141. Nippon Shokubai (JP) Recent Developments/Updates
Table 142. Nippon Shokubai (JP) Competitive Strengths & Weaknesses
Table 143. ScinoPharm (TW) Basic Information, Manufacturing Base and Competitors
Table 144. ScinoPharm (TW) Major Business
Table 145. ScinoPharm (TW) Peptide API CDMO Services Product and Services
Table 146. ScinoPharm (TW) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 147. ScinoPharm (TW) Recent Developments/Updates
Table 148. ScinoPharm (TW) Competitive Strengths & Weaknesses
Table 149. ChengDu ShengNuo Biotec (CN) Basic Information, Manufacturing Base and Competitors
Table 150. ChengDu ShengNuo Biotec (CN) Major Business
Table 151. ChengDu ShengNuo Biotec (CN) Peptide API CDMO Services Product and Services
Table 152. ChengDu ShengNuo Biotec (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 153. ChengDu ShengNuo Biotec (CN) Recent Developments/Updates
Table 154. ChengDu ShengNuo Biotec (CN) Competitive Strengths & Weaknesses
Table 155. WuXi TIDES (CN) Basic Information, Manufacturing Base and Competitors
Table 156. WuXi TIDES (CN) Major Business
Table 157. WuXi TIDES (CN) Peptide API CDMO Services Product and Services
Table 158. WuXi TIDES (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 159. WuXi TIDES (CN) Recent Developments/Updates
Table 160. WuXi TIDES (CN) Competitive Strengths & Weaknesses
Table 161. Asymchem (CN) Basic Information, Manufacturing Base and Competitors
Table 162. Asymchem (CN) Major Business
Table 163. Asymchem (CN) Peptide API CDMO Services Product and Services
Table 164. Asymchem (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 165. Asymchem (CN) Recent Developments/Updates
Table 166. Asymchem (CN) Competitive Strengths & Weaknesses
Table 167. Medtide (CN) Basic Information, Manufacturing Base and Competitors
Table 168. Medtide (CN) Major Business
Table 169. Medtide (CN) Peptide API CDMO Services Product and Services
Table 170. Medtide (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 171. Medtide (CN) Recent Developments/Updates
Table 172. Medtide (CN) Competitive Strengths & Weaknesses
Table 173. Jiuzhou Pharma (CN) Basic Information, Manufacturing Base and Competitors
Table 174. Jiuzhou Pharma (CN) Major Business
Table 175. Jiuzhou Pharma (CN) Peptide API CDMO Services Product and Services
Table 176. Jiuzhou Pharma (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 177. Jiuzhou Pharma (CN) Recent Developments/Updates
Table 178. Jiuzhou Pharma (CN) Competitive Strengths & Weaknesses
Table 179. Hybio Pharmaceutical (CN) Basic Information, Manufacturing Base and Competitors
Table 180. Hybio Pharmaceutical (CN) Major Business
Table 181. Hybio Pharmaceutical (CN) Peptide API CDMO Services Product and Services
Table 182. Hybio Pharmaceutical (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 183. Hybio Pharmaceutical (CN) Recent Developments/Updates
Table 184. Hybio Pharmaceutical (CN) Competitive Strengths & Weaknesses
Table 185. JYMed Peptide (CN) Basic Information, Manufacturing Base and Competitors
Table 186. JYMed Peptide (CN) Major Business
Table 187. JYMed Peptide (CN) Peptide API CDMO Services Product and Services
Table 188. JYMed Peptide (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 189. JYMed Peptide (CN) Recent Developments/Updates
Table 190. JYMed Peptide (CN) Competitive Strengths & Weaknesses
Table 191. Global Key Players of Peptide API CDMO Services Upstream (Raw Materials)
Table 192. Global Peptide API CDMO Services Typical Customers
Table 1. World Peptide API CDMO Services Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Peptide API CDMO Services Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Peptide API CDMO Services Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Peptide API CDMO Services Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Peptide API CDMO Services Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Peptide API CDMO Services Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Peptide API CDMO Services Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Peptide API CDMO Services Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Peptide API CDMO Services Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Peptide API CDMO Services Players in 2025
Table 12. World Peptide API CDMO Services Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Peptide API CDMO Services Company Evaluation Quadrant
Table 14. Head Office of Key Peptide API CDMO Services Players
Table 15. Peptide API CDMO Services Market: Company Product Type Footprint
Table 16. Peptide API CDMO Services Market: Company Product Application Footprint
Table 17. Peptide API CDMO Services Mergers & Acquisitions Activity
Table 18. United States VS China Peptide API CDMO Services Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Peptide API CDMO Services Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Peptide API CDMO Services Companies, Headquarters (States, Country)
Table 21. United States Based Companies Peptide API CDMO Services Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Peptide API CDMO Services Revenue Market Share (2021-2026)
Table 23. China Based Peptide API CDMO Services Companies, Headquarters (Province, Country)
Table 24. China Based Companies Peptide API CDMO Services Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Peptide API CDMO Services Revenue Market Share (2021-2026)
Table 26. Rest of World Based Peptide API CDMO Services Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Peptide API CDMO Services Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Peptide API CDMO Services Revenue Market Share (2021-2026)
Table 29. World Peptide API CDMO Services Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Peptide API CDMO Services Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Peptide API CDMO Services Market Size by Type (2027-2032) & (USD Million)
Table 32. World Peptide API CDMO Services Market Size by Synthesis Technology, (USD Million), 2021 & 2025 & 2032
Table 33. World Peptide API CDMO Services Market Size Value by Synthesis Technology (2021-2026) & (USD Million)
Table 34. World Peptide API CDMO Services Market Size by Synthesis Technology (2027-2032) & (USD Million)
Table 35. World Peptide API CDMO Services Market Size by Capacity Tier, (USD Million), 2021 & 2025 & 2032
Table 36. World Peptide API CDMO Services Market Size Value by Capacity Tier (2021-2026) & (USD Million)
Table 37. World Peptide API CDMO Services Market Size by Capacity Tier (2027-2032) & (USD Million)
Table 38. World Peptide API CDMO Services Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Peptide API CDMO Services Market Size by Application (2021-2026) & (USD Million)
Table 40. World Peptide API CDMO Services Market Size by Application (2027-2032) & (USD Million)
Table 41. PolyPeptide (CH) Basic Information, Manufacturing Base and Competitors
Table 42. PolyPeptide (CH) Major Business
Table 43. PolyPeptide (CH) Peptide API CDMO Services Product and Services
Table 44. PolyPeptide (CH) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. PolyPeptide (CH) Recent Developments/Updates
Table 46. PolyPeptide (CH) Competitive Strengths & Weaknesses
Table 47. Bachem (CH) Basic Information, Manufacturing Base and Competitors
Table 48. Bachem (CH) Major Business
Table 49. Bachem (CH) Peptide API CDMO Services Product and Services
Table 50. Bachem (CH) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Bachem (CH) Recent Developments/Updates
Table 52. Bachem (CH) Competitive Strengths & Weaknesses
Table 53. AmbioPharm (US) Basic Information, Manufacturing Base and Competitors
Table 54. AmbioPharm (US) Major Business
Table 55. AmbioPharm (US) Peptide API CDMO Services Product and Services
Table 56. AmbioPharm (US) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. AmbioPharm (US) Recent Developments/Updates
Table 58. AmbioPharm (US) Competitive Strengths & Weaknesses
Table 59. CordenPharma (CH) Basic Information, Manufacturing Base and Competitors
Table 60. CordenPharma (CH) Major Business
Table 61. CordenPharma (CH) Peptide API CDMO Services Product and Services
Table 62. CordenPharma (CH) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. CordenPharma (CH) Recent Developments/Updates
Table 64. CordenPharma (CH) Competitive Strengths & Weaknesses
Table 65. CPC Scientific (US) Basic Information, Manufacturing Base and Competitors
Table 66. CPC Scientific (US) Major Business
Table 67. CPC Scientific (US) Peptide API CDMO Services Product and Services
Table 68. CPC Scientific (US) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. CPC Scientific (US) Recent Developments/Updates
Table 70. CPC Scientific (US) Competitive Strengths & Weaknesses
Table 71. Piramal Pharma Solutions (IN) Basic Information, Manufacturing Base and Competitors
Table 72. Piramal Pharma Solutions (IN) Major Business
Table 73. Piramal Pharma Solutions (IN) Peptide API CDMO Services Product and Services
Table 74. Piramal Pharma Solutions (IN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Piramal Pharma Solutions (IN) Recent Developments/Updates
Table 76. Piramal Pharma Solutions (IN) Competitive Strengths & Weaknesses
Table 77. Almac Group (UK) Basic Information, Manufacturing Base and Competitors
Table 78. Almac Group (UK) Major Business
Table 79. Almac Group (UK) Peptide API CDMO Services Product and Services
Table 80. Almac Group (UK) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Almac Group (UK) Recent Developments/Updates
Table 82. Almac Group (UK) Competitive Strengths & Weaknesses
Table 83. Aspen API (ZA) Basic Information, Manufacturing Base and Competitors
Table 84. Aspen API (ZA) Major Business
Table 85. Aspen API (ZA) Peptide API CDMO Services Product and Services
Table 86. Aspen API (ZA) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Aspen API (ZA) Recent Developments/Updates
Table 88. Aspen API (ZA) Competitive Strengths & Weaknesses
Table 89. Neuland Laboratories (IN) Basic Information, Manufacturing Base and Competitors
Table 90. Neuland Laboratories (IN) Major Business
Table 91. Neuland Laboratories (IN) Peptide API CDMO Services Product and Services
Table 92. Neuland Laboratories (IN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Neuland Laboratories (IN) Recent Developments/Updates
Table 94. Neuland Laboratories (IN) Competitive Strengths & Weaknesses
Table 95. USV (IN) Basic Information, Manufacturing Base and Competitors
Table 96. USV (IN) Major Business
Table 97. USV (IN) Peptide API CDMO Services Product and Services
Table 98. USV (IN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. USV (IN) Recent Developments/Updates
Table 100. USV (IN) Competitive Strengths & Weaknesses
Table 101. Aurigene Pharmaceutical Services (IN) Basic Information, Manufacturing Base and Competitors
Table 102. Aurigene Pharmaceutical Services (IN) Major Business
Table 103. Aurigene Pharmaceutical Services (IN) Peptide API CDMO Services Product and Services
Table 104. Aurigene Pharmaceutical Services (IN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. Aurigene Pharmaceutical Services (IN) Recent Developments/Updates
Table 106. Aurigene Pharmaceutical Services (IN) Competitive Strengths & Weaknesses
Table 107. PeptiStar (JP) Basic Information, Manufacturing Base and Competitors
Table 108. PeptiStar (JP) Major Business
Table 109. PeptiStar (JP) Peptide API CDMO Services Product and Services
Table 110. PeptiStar (JP) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. PeptiStar (JP) Recent Developments/Updates
Table 112. PeptiStar (JP) Competitive Strengths & Weaknesses
Table 113. BCN Peptides (ES) Basic Information, Manufacturing Base and Competitors
Table 114. BCN Peptides (ES) Major Business
Table 115. BCN Peptides (ES) Peptide API CDMO Services Product and Services
Table 116. BCN Peptides (ES) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 117. BCN Peptides (ES) Recent Developments/Updates
Table 118. BCN Peptides (ES) Competitive Strengths & Weaknesses
Table 119. Creative Peptides (US) Basic Information, Manufacturing Base and Competitors
Table 120. Creative Peptides (US) Major Business
Table 121. Creative Peptides (US) Peptide API CDMO Services Product and Services
Table 122. Creative Peptides (US) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 123. Creative Peptides (US) Recent Developments/Updates
Table 124. Creative Peptides (US) Competitive Strengths & Weaknesses
Table 125. Space Peptides (CH) Basic Information, Manufacturing Base and Competitors
Table 126. Space Peptides (CH) Major Business
Table 127. Space Peptides (CH) Peptide API CDMO Services Product and Services
Table 128. Space Peptides (CH) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 129. Space Peptides (CH) Recent Developments/Updates
Table 130. Space Peptides (CH) Competitive Strengths & Weaknesses
Table 131. Cambrex (US) Basic Information, Manufacturing Base and Competitors
Table 132. Cambrex (US) Major Business
Table 133. Cambrex (US) Peptide API CDMO Services Product and Services
Table 134. Cambrex (US) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 135. Cambrex (US) Recent Developments/Updates
Table 136. Cambrex (US) Competitive Strengths & Weaknesses
Table 137. Nippon Shokubai (JP) Basic Information, Manufacturing Base and Competitors
Table 138. Nippon Shokubai (JP) Major Business
Table 139. Nippon Shokubai (JP) Peptide API CDMO Services Product and Services
Table 140. Nippon Shokubai (JP) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 141. Nippon Shokubai (JP) Recent Developments/Updates
Table 142. Nippon Shokubai (JP) Competitive Strengths & Weaknesses
Table 143. ScinoPharm (TW) Basic Information, Manufacturing Base and Competitors
Table 144. ScinoPharm (TW) Major Business
Table 145. ScinoPharm (TW) Peptide API CDMO Services Product and Services
Table 146. ScinoPharm (TW) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 147. ScinoPharm (TW) Recent Developments/Updates
Table 148. ScinoPharm (TW) Competitive Strengths & Weaknesses
Table 149. ChengDu ShengNuo Biotec (CN) Basic Information, Manufacturing Base and Competitors
Table 150. ChengDu ShengNuo Biotec (CN) Major Business
Table 151. ChengDu ShengNuo Biotec (CN) Peptide API CDMO Services Product and Services
Table 152. ChengDu ShengNuo Biotec (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 153. ChengDu ShengNuo Biotec (CN) Recent Developments/Updates
Table 154. ChengDu ShengNuo Biotec (CN) Competitive Strengths & Weaknesses
Table 155. WuXi TIDES (CN) Basic Information, Manufacturing Base and Competitors
Table 156. WuXi TIDES (CN) Major Business
Table 157. WuXi TIDES (CN) Peptide API CDMO Services Product and Services
Table 158. WuXi TIDES (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 159. WuXi TIDES (CN) Recent Developments/Updates
Table 160. WuXi TIDES (CN) Competitive Strengths & Weaknesses
Table 161. Asymchem (CN) Basic Information, Manufacturing Base and Competitors
Table 162. Asymchem (CN) Major Business
Table 163. Asymchem (CN) Peptide API CDMO Services Product and Services
Table 164. Asymchem (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 165. Asymchem (CN) Recent Developments/Updates
Table 166. Asymchem (CN) Competitive Strengths & Weaknesses
Table 167. Medtide (CN) Basic Information, Manufacturing Base and Competitors
Table 168. Medtide (CN) Major Business
Table 169. Medtide (CN) Peptide API CDMO Services Product and Services
Table 170. Medtide (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 171. Medtide (CN) Recent Developments/Updates
Table 172. Medtide (CN) Competitive Strengths & Weaknesses
Table 173. Jiuzhou Pharma (CN) Basic Information, Manufacturing Base and Competitors
Table 174. Jiuzhou Pharma (CN) Major Business
Table 175. Jiuzhou Pharma (CN) Peptide API CDMO Services Product and Services
Table 176. Jiuzhou Pharma (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 177. Jiuzhou Pharma (CN) Recent Developments/Updates
Table 178. Jiuzhou Pharma (CN) Competitive Strengths & Weaknesses
Table 179. Hybio Pharmaceutical (CN) Basic Information, Manufacturing Base and Competitors
Table 180. Hybio Pharmaceutical (CN) Major Business
Table 181. Hybio Pharmaceutical (CN) Peptide API CDMO Services Product and Services
Table 182. Hybio Pharmaceutical (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 183. Hybio Pharmaceutical (CN) Recent Developments/Updates
Table 184. Hybio Pharmaceutical (CN) Competitive Strengths & Weaknesses
Table 185. JYMed Peptide (CN) Basic Information, Manufacturing Base and Competitors
Table 186. JYMed Peptide (CN) Major Business
Table 187. JYMed Peptide (CN) Peptide API CDMO Services Product and Services
Table 188. JYMed Peptide (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 189. JYMed Peptide (CN) Recent Developments/Updates
Table 190. JYMed Peptide (CN) Competitive Strengths & Weaknesses
Table 191. Global Key Players of Peptide API CDMO Services Upstream (Raw Materials)
Table 192. Global Peptide API CDMO Services Typical Customers
LIST OF FIGURES
Figure 1. Peptide API CDMO Services Picture
Figure 2. World Peptide API CDMO Services Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Peptide API CDMO Services Total Revenue (2021-2032) & (USD Million)
Figure 4. World Peptide API CDMO Services Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Peptide API CDMO Services Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Peptide API CDMO Services Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Peptide API CDMO Services Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Peptide API CDMO Services Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Peptide API CDMO Services Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Peptide API CDMO Services Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Peptide API CDMO Services Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Peptide API CDMO Services Revenue (2021-2032) & (USD Million)
Figure 13. Peptide API CDMO Services Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 16. World Peptide API CDMO Services Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 18. China Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 23. India Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Peptide API CDMO Services by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Peptide API CDMO Services Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Peptide API CDMO Services Markets in 2025
Figure 27. United States VS China: Peptide API CDMO Services Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Peptide API CDMO Services Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Peptide API CDMO Services Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Peptide API CDMO Services Market Size Market Share by Type in 2025
Figure 31. GMP Services
Figure 32. Non-GMP Services
Figure 33. World Peptide API CDMO Services Market Size Market Share by Type (2021-2032)
Figure 34. World Peptide API CDMO Services Market Size by Synthesis Technology, (USD Million), 2021 & 2025 & 2032
Figure 35. World Peptide API CDMO Services Market Size Market Share by Synthesis Technology in 2025
Figure 36. SPPS
Figure 37. LPPS
Figure 38. Hybrid Technology
Figure 39. World Peptide API CDMO Services Market Size Market Share by Synthesis Technology (2021-2032)
Figure 40. World Peptide API CDMO Services Market Size by Capacity Tier, (USD Million), 2021 & 2025 & 2032
Figure 41. World Peptide API CDMO Services Market Size Market Share by Capacity Tier in 2025
Figure 42. Small-Scale (mg?g)
Figure 43. Medium-Scale (g?kg)
Figure 44. Large-Scale (kg?t)
Figure 45. World Peptide API CDMO Services Market Size Market Share by Capacity Tier (2021-2032)
Figure 46. World Peptide API CDMO Services Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 47. World Peptide API CDMO Services Market Size Market Share by Application in 2025
Figure 48. Commercial
Figure 49. Scientific Research
Figure 50. Other
Figure 51. World Peptide API CDMO Services Market Size Market Share by Application (2021-2032)
Figure 52. Peptide API CDMO Services Industrial Chain
Figure 53. Methodology
Figure 54. Research Process and Data Source
Figure 1. Peptide API CDMO Services Picture
Figure 2. World Peptide API CDMO Services Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Peptide API CDMO Services Total Revenue (2021-2032) & (USD Million)
Figure 4. World Peptide API CDMO Services Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Peptide API CDMO Services Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Peptide API CDMO Services Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Peptide API CDMO Services Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Peptide API CDMO Services Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Peptide API CDMO Services Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Peptide API CDMO Services Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Peptide API CDMO Services Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Peptide API CDMO Services Revenue (2021-2032) & (USD Million)
Figure 13. Peptide API CDMO Services Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 16. World Peptide API CDMO Services Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 18. China Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 23. India Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Peptide API CDMO Services by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Peptide API CDMO Services Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Peptide API CDMO Services Markets in 2025
Figure 27. United States VS China: Peptide API CDMO Services Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Peptide API CDMO Services Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Peptide API CDMO Services Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Peptide API CDMO Services Market Size Market Share by Type in 2025
Figure 31. GMP Services
Figure 32. Non-GMP Services
Figure 33. World Peptide API CDMO Services Market Size Market Share by Type (2021-2032)
Figure 34. World Peptide API CDMO Services Market Size by Synthesis Technology, (USD Million), 2021 & 2025 & 2032
Figure 35. World Peptide API CDMO Services Market Size Market Share by Synthesis Technology in 2025
Figure 36. SPPS
Figure 37. LPPS
Figure 38. Hybrid Technology
Figure 39. World Peptide API CDMO Services Market Size Market Share by Synthesis Technology (2021-2032)
Figure 40. World Peptide API CDMO Services Market Size by Capacity Tier, (USD Million), 2021 & 2025 & 2032
Figure 41. World Peptide API CDMO Services Market Size Market Share by Capacity Tier in 2025
Figure 42. Small-Scale (mg?g)
Figure 43. Medium-Scale (g?kg)
Figure 44. Large-Scale (kg?t)
Figure 45. World Peptide API CDMO Services Market Size Market Share by Capacity Tier (2021-2032)
Figure 46. World Peptide API CDMO Services Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 47. World Peptide API CDMO Services Market Size Market Share by Application in 2025
Figure 48. Commercial
Figure 49. Scientific Research
Figure 50. Other
Figure 51. World Peptide API CDMO Services Market Size Market Share by Application (2021-2032)
Figure 52. Peptide API CDMO Services Industrial Chain
Figure 53. Methodology
Figure 54. Research Process and Data Source
